Result of the 2017 Annual General Meeting
April 25, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the Notice of Meeting were decided by poll vote. The results of the poll are as follows:
| Resolutions | For (including discretionary votes) | % | Against | % | Votes cast as a % of relevant shares in issue | Withheld |
| Ordinary Resolutions | ||||||
| 1. To receive the Company's Annual Report and Accounts for the year ended December 31, 2016. | 654,818,375 | 98.84% | 7,707,875 | 1.16% | 73.04% | 4,881,183 |
| 2. To approve the Directors' Remuneration Report. | 615,163,095 | 93.22% | 44,723,057 | 6.78% | 72.75% | 7,521,281 |
| 3. To re-elect Dominic Blakemore as a Director. | 649,117,820 | 98.05% | 12,928,333 | 1.95% | 72.99% | 5,361,280 |
| 4. To re-elect Olivier Bohuon as a Director. | 627,642,447 | 94.87% | 33,920,776 | 5.13% | 72.94% | 5,844,210 |
| 5. To re-elect William Burns as a Director. | 665,784,255 | 99.86% | 960,666 | 0.14% | 73.51% | 662,512 |
| 6. To elect Ian Clark as a Director. | 651,027,149 | 97.63% | 15,797,431 | 2.37% | 73.52% | 582,853 |
| 7. To elect Gail Fosler as a Director. | 661,335,866 | 99.18% | 5,499,058 | 0.82% | 73.52% | 572,509 |
| 8. To re-elect Steven Gillis as a Director. | 635,977,566 | 95.40% | 30,649,403 | 4.60% | 73.50% | 780,464 |
| 9. To re-elect David Ginsburg as a Director. | 666,231,111 | 99.91% | 593,588 | 0.09% | 73.52% | 582,734 |
| 10. To re-elect Susan Kilsby as a Director. | 659,834,334 | 99.01% | 6,565,404 | 0.99% | 73.47% | 1,007,695 |
| 11. To re-elect Sara Mathew as a Director. | 660,030,658 | 98.98% | 6,802,836 | 1.02% | 73.52% | 573,939 |
| 12. To re-elect Anne Minto as a Director. | 657,515,406 | 99.31% | 4,576,118 | 0.69% | 73.00% | 5,315,909 |
| 13. To re-elect Flemming Ornskov as a Director. | 666,498,607 | 99.95% | 322,419 | 0.05% | 73.52% | 586,407 |
| 14. To re-elect Jeffrey Poulton as a Director. | 663,597,002 | 99.51% | 3,236,158 | 0.49% | 73.52% | 574,273 |
| 15. To elect Albert Stroucken as a Director. | 660,769,699 | 99.09% | 6,047,544 | 0.91% | 73.52% | 590,190 |
| 16. To re-appoint Deloitte LLP as the Company's Auditor. | 596,710,936 | 89.64% | 68,985,657 | 10.36% | 73.39% | 1,710,840 |
| 17. To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor. | 613,970,704 | 92.24% | 51,651,020 | 7.76% | 73.39% | 1,785,709 |
| 18. To authorize the allotment of shares. | 622,880,755 | 93.40% | 43,989,439 | 6.60% | 73.52% | 537,239 |
| Special Resolutions | ||||||
| 19. To authorize the general disapplication of pre-emption rights. | 647,605,695 | 97.72% | 15,078,442 | 2.28% | 73.06% | 4,723,296 |
| 20. To authorize the specific disapplication of pre-emption rights. | 632,770,742 | 95.48% | 29,932,382 | 4.52% | 73.06% | 4,704,309 |
| 21. To authorize purchases of own shares. | 658,828,861 | 98.87% | 7,499,007 | 1.13% | 73.46% | 1,079,565 |
| 22. To adopt new Articles of Association. | 660,636,265 | 99.08% | 6,130,317 | 0.92% | 73.51% | 640,851 |
| 23. To approve the notice period for general meetings. | 619,638,682 | 93.34% | 44,232,588 | 6.66% | 73.19% | 3,536,163 |
As at the record date, April 23, 2017, the Company had 907,025,186 Ordinary Shares of 5 pence each in issue (excluding shares held in treasury). Shareholders are entitled to one vote per share. A vote "withheld" is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.
In accordance with Listing Rule 9.6.2R, copies of the relevant resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
